ALSO NOTED: Sinclair Pharma shares drop; Korea cracks down on bribery;

> Sinclair Pharma saw its shares drop 12 percent after its marketing partner OraPharma delayed the U.S. introduction of Decapinol, a mouth rinse for gum disease. Report

> A new study shows the abortion pill is no more dangerous than the surgical form of abortion. Some researchers had theorized that use of RU-486 might increase the risk of future miscarriage or tubal pregnancy; those fears appear to be unfounded. Report

> Korean regulators have caught 17 mid-size and large drug makers bribing hospitals with rebates, the country's Fair Trade Commission announced. Its anti-bribery crackdown will now expand to 200 small local drug companies, the agency said. The names of the companies involved were not released. Report

And Finally... When Warren Buffett invests in your company, the attention is a backhanded compliment: Buffett tends to nab you when you're down, so if he's buying, you're not flying. And right now, his eyes appear to be on Pharma. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.